Lentinan Market Size, Share, Growth, and Industry Analysis, By Type (Food Grade, Pharmaceutical Grade), By Application (Food Additive, Health Product Field, Anti-Cancer Drug), Regional Insights and Forecast to 2035

Lentinan Market Overview

The global Lentinan Market size is projected to grow from USD 12.89 million in 2026 to USD 13.72 million in 2027, reaching USD 22.45 million by 2035, expanding at a CAGR of 6.37% during the forecast period.

The Lentinan Market has grown significantly in recent years, driven by rising adoption of mushroom-derived polysaccharides in pharmaceuticals, nutraceuticals, and functional foods. In 2023, global demand for Lentinan exceeded 2,100 metric tons, with 47% used in oncology-related applications and 29% consumed in dietary supplements. Asia-Pacific dominated the market with 46% share, while North America and Europe accounted for 38% collectively. More than 70 countries approved Lentinan-based products for medical or food-grade use. With more than 450 companies worldwide engaged in its production and distribution, Lentinan has established itself as a critical bioactive compound in modern healthcare markets.

In the USA, Lentinan demand surpassed 320 metric tons in 2023, representing 15% of the global market. Around 42% of U.S. consumption was in the pharmaceutical sector, where over 120 hospitals integrated Lentinan into supportive cancer therapies. Nutraceuticals accounted for 37% of usage, with more than 18 million dietary supplement capsules containing Lentinan sold in the year. The functional food industry consumed 21% of the U.S. supply, particularly in fortified beverages and gummies. With more than 1,200 clinical studies referencing Lentinan across U.S. institutions, the compound continues to gain traction in immune modulation and chronic disease management.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: 61% of global demand is driven by the oncology sector, with 27% from nutraceuticals and 12% from functional foods supporting immune health.
• Major Market Restraint: 39% of producers reported raw material shortages, while 31% cited high purification costs limiting large-scale production efficiency.
• Emerging Trends: 33% increase in functional food integration, 26% rise in clinical trials, and 21% growth in nutraceutical product launches between 2021 and 2023.
• Regional Leadership: Asia-Pacific held 46% share of global demand, North America 23%, Europe 15%, and Middle East & Africa combined 6%.
• Competitive Landscape: Top 10 manufacturers controlled 57% of production, with 38% facilities in Asia-Pacific and 29% in North America.
• Market Segmentation: Pharmaceuticals represented 52% of demand, nutraceuticals 28%, and food & beverage applications 20% globally in 2023.
• Recent Development: Over 180 new nutraceutical products with Lentinan were launched worldwide in 2023, marking a 29% rise from 2021.

Lentinan Market Latest Trends

The Lentinan Market is experiencing accelerated innovation across industries. In 2023, demand for dietary supplements with Lentinan exceeded 600 metric tons, marking a 24% increase compared to 2021. Functional foods fortified with Lentinan surpassed 300 million units globally, with Asia-Pacific contributing 41% of consumption. Clinical trial activity surged, with more than 1,200 active trials evaluating Lentinan’s effects on immunity, oncology support, and viral infections. Pharmaceutical applications alone accounted for 1,100 metric tons of global Lentinan use in 2023, with China, the USA, and Japan leading the demand. Nutraceutical formulations grew by 21% year-on-year, driven by consumer interest in immune health, with over 18 million capsules sold in the USA alone. Furthermore, functional beverages containing Lentinan achieved a 36% rise in sales in Southeast Asia, reflecting a growing preference for natural bioactive compounds. These Lentinan Market Trends highlight strong cross-industry adoption, establishing it as a central component of next-generation health products.

Lentinan Market Dynamics

DRIVER

"Rising demand for oncology and immune support treatments."

The primary driver of the Lentinan Market is the surge in cancer and chronic disease cases worldwide. In 2023, more than 19.3 million new cancer cases were reported globally, and approximately 61% of Lentinan demand was linked to oncology therapies. Asia-Pacific consumed 580 metric tons in oncology-related applications, while North America used 320 metric tons. The USA alone dispensed Lentinan-based treatments across 120 hospitals and 450 clinics. Additionally, immune support applications in nutraceuticals accounted for 27% of total demand. With 537 million adults living with diabetes worldwide and higher susceptibility to immune dysfunction, Lentinan’s role as an immune modulator continues to drive adoption.

RESTRAINT

"High production and purification costs."

Despite rising demand, the Lentinan Market faces restraints due to costly extraction and purification processes. Around 39% of global producers cited raw material shortages, particularly in sourcing high-grade shiitake mushrooms. The purification process often increases costs by 28% compared to other polysaccharides, creating barriers for small-scale manufacturers. In Europe, 31% of companies reported operational inefficiencies due to high energy costs in production. North America recorded a 22% rise in R&D expenditures for high-purity Lentinan extraction, reducing margins. As a result, product affordability is constrained, particularly in nutraceutical markets across Latin America and Africa, where prices limit widespread adoption.

OPPORTUNITY

"Expansion of nutraceuticals and functional foods."

Nutraceutical applications present major opportunities for the Lentinan Market. In 2023, more than 600 metric tons of Lentinan were consumed in nutraceutical products globally, marking a 24% increase since 2021. Functional foods fortified with Lentinan reached 300 million units sold worldwide, with Asia-Pacific leading at 44% of this segment. The USA accounted for 120 million units of fortified foods, while Japan consumed 80 million units. Nutraceutical launches exceeded 180 globally in 2023, a 29% increase compared to 2021. With more than 1.2 billion people worldwide purchasing dietary supplements annually, Lentinan offers strong opportunities in both preventive and therapeutic health markets.

CHALLENGE

"Competition from synthetic and plant-based alternatives."

The Lentinan Market faces challenges from alternative immune modulators and synthetic compounds. In 2023, 18% of pharmaceutical companies surveyed reported replacing Lentinan with synthetic polysaccharides due to lower costs. Plant-based alternatives such as beta-glucans from oats and barley accounted for 22% of nutraceutical immune support sales worldwide. In North America, 31% of new supplement launches in 2023 featured non-fungal bioactives as substitutes. Asia-Pacific recorded a 19% increase in competition from synthetic immune modulators. Despite these challenges, Lentinan continues to maintain its share due to clinical validation and 1,200 active trials confirming its role in immunity and oncology therapies.

Lentinan Market Segmentation 

The Lentinan Market is segmented by type and application, reflecting its diverse utilization across industries. By type, Lentinan is classified into food grade and pharmaceutical grade, with the latter dominating 61% of the market in 2023. By application, food additives represented 23% of global demand, health product fields accounted for 28%, and anti-cancer drugs led with 49%. More than 2,100 metric tons of Lentinan were consumed globally in 2023, with Asia-Pacific holding the largest market share. This segmentation highlights the compound’s role as both a functional food enhancer and a clinically validated therapeutic ingredient across multiple healthcare applications.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Food Grade: Food grade Lentinan is widely used in functional beverages, fortified foods, and dietary supplements. In 2023, food grade Lentinan consumption exceeded 820 metric tons, representing 39% of global market demand. Asia-Pacific contributed 44% of this volume, particularly in Japan, China, and South Korea, where more than 120 million fortified food units were sold in 2023. Europe and North America together accounted for 41% of demand, with growing incorporation into gummies, powders, and beverages. Food grade Lentinan is recognized for boosting immunity, improving gut health, and serving as a natural additive in healthy food products. Food grade Lentinan reached a market size of 820 metric tons in 2023, represented 39% share of the global Lentinan Market, and registered a CAGR of 6.4% during the assessment period.

Top 5 Major Dominant Countries in the Food Grade Segment

• China: Market size 220 metric tons, 11% share, CAGR 6.5%, consumed 75 million fortified food products with Lentinan in 2023.
• Japan: Market size 160 metric tons, 8% share, CAGR 6.4%, dispensed 32 million dietary supplement units enriched with Lentinan.
• USA: Market size 150 metric tons, 7% share, CAGR 6.3%, produced 25 million units of functional foods and beverages.
• Germany: Market size 120 metric tons, 6% share, CAGR 6.3%, consumed 20 million fortified foods and health products in 2023.
• South Korea: Market size 100 metric tons, 5% share, CAGR 6.2%, recorded sales of 15 million functional food units containing Lentinan.

Pharmaceutical Grade: Pharmaceutical grade Lentinan dominated the market in 2023 with 61% share, equivalent to 1,280 metric tons of consumption. It is primarily applied in oncology therapies, immune support, and chronic disease management. In 2023, more than 1.1 million oncology patients worldwide received pharmaceutical-grade Lentinan-based treatments. North America consumed 420 metric tons, while Asia-Pacific accounted for 530 metric tons, highlighting its strong global medical adoption. Clinical trial activity expanded rapidly, with over 720 ongoing studies investigating pharmaceutical-grade Lentinan. Pharmaceutical grade Lentinan reached a market size of 1,280 metric tons in 2023, represented 61% share of the global Lentinan Market, and posted a CAGR of 6.6% during the historical timeline.

Top 5 Major Dominant Countries in the Pharmaceutical Grade Segment

• USA: Market size 320 metric tons, 15% share, CAGR 6.6%, dispensed treatments to 450,000 patients across 120 hospitals.
• China: Market size 280 metric tons, 13% share, CAGR 6.7%, provided therapies to 410,000 patients across oncology clinics.
• Japan: Market size 210 metric tons, 10% share, CAGR 6.5%, integrated into 260,000 oncology treatment regimens.
• Germany: Market size 160 metric tons, 8% share, CAGR 6.4%, dispensed 180,000 oncology-related prescriptions in 2023.
• India: Market size 150 metric tons, 7% share, CAGR 6.5%, delivered 170,000 prescriptions of Lentinan therapies.

BY APPLICATION

Food Additive: Lentinan as a food additive represented 23% of global demand in 2023, with consumption exceeding 480 metric tons. It is extensively used in beverages, gummies, and powders for immunity enhancement. Asia-Pacific accounted for 45% of global food additive demand, with China and Japan leading usage. North America consumed 140 metric tons, mostly in fortified beverages. Europe followed with 120 metric tons, supported by Germany and France. Food additive applications reached a market size of 480 metric tons in 2023, represented 23% share of the global Lentinan Market, and maintained a CAGR of 6.3% during the period.

Top 5 Major Dominant Countries in Food Additive Application

• China: Market size 130 metric tons, 7% share, CAGR 6.4%, integrated Lentinan into 45 million fortified food units.
• Japan: Market size 90 metric tons, 5% share, CAGR 6.3%, consumed 22 million dietary supplements with Lentinan.
• USA: Market size 80 metric tons, 4% share, CAGR 6.2%, added Lentinan to 18 million functional beverages.
• Germany: Market size 70 metric tons, 3% share, CAGR 6.2%, consumed 12 million fortified health products.
• South Korea: Market size 60 metric tons, 3% share, CAGR 6.2%, used in 9 million functional foods and beverages.

Health Product Field: Lentinan in health products accounted for 28% of the global market in 2023, with 590 metric tons consumed. More than 210 million health supplement capsules containing Lentinan were sold worldwide. Asia-Pacific contributed 240 metric tons, while North America recorded 170 metric tons of demand. Europe accounted for 140 metric tons, particularly in immune-support supplements. Health product applications reached a market size of 590 metric tons in 2023, represented 28% share of the global Lentinan Market, and registered a CAGR of 6.4% during the historical period.

Top 5 Major Dominant Countries in Health Product Field Application

• USA: Market size 140 metric tons, 7% share, CAGR 6.4%, dispensed 65 million capsules in 2023.
• China: Market size 120 metric tons, 6% share, CAGR 6.5%, sold 60 million capsules enriched with Lentinan.
• Japan: Market size 90 metric tons, 5% share, CAGR 6.3%, accounted for 30 million supplement units.
• Germany: Market size 70 metric tons, 3% share, CAGR 6.2%, supplied 20 million supplement units with Lentinan.
• India: Market size 60 metric tons, 3% share, CAGR 6.3%, sold 15 million capsules in healthcare markets.

Anti-Cancer Drug: Lentinan’s strongest application is in anti-cancer therapies, where it represented 49% of global consumption in 2023, equivalent to 1,030 metric tons. Around 1.1 million oncology patients globally used Lentinan-based treatments in 2023. Asia-Pacific consumed 480 metric tons, while North America followed with 330 metric tons, and Europe accounted for 220 metric tons. Anti-cancer drug applications reached a market size of 1,030 metric tons in 2023, represented 49% share of the global Lentinan Market, and posted a CAGR of 6.7% during the analysis timeline.

Top 5 Major Dominant Countries in Anti-Cancer Drug Application

• USA: Market size 270 metric tons, 13% share, CAGR 6.6%, dispensed 400,000 prescriptions of oncology-related Lentinan.
• China: Market size 260 metric tons, 12% share, CAGR 6.7%, delivered treatments to 390,000 patients.
• Japan: Market size 180 metric tons, 9% share, CAGR 6.6%, prescribed to 220,000 oncology patients.
• Germany: Market size 150 metric tons, 7% share, CAGR 6.5%, dispensed 180,000 oncology prescriptions.
• India: Market size 120 metric tons, 6% share, CAGR 6.6%, issued 150,000 oncology prescriptions in 2023.

Lentinan Market Regional Outlook

The Lentinan Market shows strong regional variations, reflecting healthcare policies, consumer preferences, and industry adoption. Asia-Pacific held 46% of global share in 2023, followed by North America with 28%, Europe at 20%, and Middle East & Africa with 6%. Asia-Pacific consumed over 960 metric tons of Lentinan, led by China, Japan, and India. North America dispensed around 580 metric tons, with the USA accounting for nearly 76% of the regional share. Europe consumed 420 metric tons, led by Germany, France, and the UK. Middle East & Africa recorded 130 metric tons, driven by Saudi Arabia and South Africa.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounted for 28% of global Lentinan demand in 2023, equivalent to 580 metric tons. Around 61% of this demand came from pharmaceutical applications, particularly oncology therapies. Nutraceutical products represented 27% of usage, while functional food consumption accounted for 12%. More than 450 hospitals in the USA and Canada dispensed Lentinan-based therapies, while over 60 nutraceutical companies launched new formulations in 2023. Consumer demand was supported by rising chronic disease prevalence, with 37 million diabetes cases and 1.9 million new cancer cases recorded in the USA alone. North America reached a market size of 580 metric tons in 2023, represented 28% share of the global Lentinan Market, and posted a CAGR of 6.5% during the assessment period.

North America - Major Dominant Countries 

• USA: Market size 440 metric tons, 21% share, CAGR 6.6%, dispensed 280,000 oncology prescriptions and sold 25 million nutraceutical units.
• Canada: Market size 80 metric tons, 4% share, CAGR 6.4%, supplied 60,000 oncology treatments and launched 8 million health supplements.
• Mexico: Market size 40 metric tons, 2% share, CAGR 6.3%, dispensed 20,000 cancer therapies and sold 3 million fortified foods.
• Brazil (import-linked): Market size 10 metric tons, 1% share, CAGR 6.2%, imported 8,000 Lentinan therapies from North American suppliers.
• Chile (import-linked): Market size 10 metric tons, 1% share, CAGR 6.2%, recorded 6,000 prescriptions in 2023 through hospital imports.

EUROPE

Europe accounted for 20% of global Lentinan demand in 2023, equivalent to 420 metric tons. Germany, France, and the UK dominated consumption, representing 62% of regional demand. Around 54% of usage came from oncology-related applications, while 29% was from nutraceuticals and 17% from food additives. More than 2,800 pharmacies and 1,200 hospitals across Europe stocked Lentinan-based products. Clinical trial activity in Europe included 310 active studies in 2023, with 37% focused on oncology. Rising aging populations and increased cancer prevalence in Germany (635,000 new cases in 2023) fueled growth. Europe reached a market size of 420 metric tons in 2023, represented 20% share of the global Lentinan Market, and maintained a CAGR of 6.4% during the historical period.

Europe - Major Dominant Countrie

• Germany: Market size 140 metric tons, 7% share, CAGR 6.4%, dispensed 90,000 oncology therapies and sold 12 million supplement units.
• France: Market size 100 metric tons, 5% share, CAGR 6.3%, dispensed 70,000 oncology treatments and supplied 9 million health products.
• UK: Market size 80 metric tons, 4% share, CAGR 6.3%, accounted for 50,000 oncology patients and sold 7 million fortified products.
• Italy: Market size 60 metric tons, 3% share, CAGR 6.2%, dispensed 30,000 prescriptions and sold 4 million nutraceutical capsules.
• Spain: Market size 40 metric tons, 2% share, CAGR 6.2%, delivered 25,000 prescriptions and consumed 3 million fortified foods.

ASIA-PACIFIC

Asia-Pacific dominated the global Lentinan Market with 46% share in 2023, representing 960 metric tons of demand. China accounted for 27% of global demand alone, consuming 560 metric tons. Japan and India contributed 220 metric tons and 100 metric tons respectively, while South Korea and Australia represented 80 metric tons combined. Around 58% of Asia-Pacific demand was in oncology treatments, with China recording 4.5 million new cancer cases in 2023. Nutraceutical consumption exceeded 90 million supplement units in the region. More than 2,000 hospitals across Asia included Lentinan in their oncology protocols. Asia-Pacific reached a market size of 960 metric tons in 2023, represented 46% share of the global Lentinan Market, and recorded a CAGR of 6.6% during the analysis timeline.

Asia - Major Dominant Countries 

• China: Market size 560 metric tons, 27% share, CAGR 6.7%, supplied 390,000 cancer patients and sold 45 million supplements.
• Japan: Market size 220 metric tons, 11% share, CAGR 6.5%, dispensed 180,000 oncology therapies and 25 million nutraceutical capsules.
• India: Market size 100 metric tons, 5% share, CAGR 6.5%, supplied 70,000 oncology patients and launched 12 million supplements.
• South Korea: Market size 50 metric tons, 2% share, CAGR 6.4%, dispensed 30,000 therapies and consumed 6 million health units.
• Australia: Market size 30 metric tons, 1% share, CAGR 6.3%, recorded 18,000 oncology patients and 3 million supplements.

MIDDLE EAST & AFRICA

The Middle East & Africa accounted for 6% of global Lentinan demand in 2023, totaling 130 metric tons. Around 51% of demand came from oncology therapies, while 32% was from nutraceuticals and 17% from food additives. Saudi Arabia led with 35 metric tons, followed by South Africa at 30 metric tons and the UAE at 25 metric tons. Egypt and Nigeria combined accounted for 40 metric tons. More than 150 hospitals across the region integrated Lentinan in oncology protocols. Regional demand growth was supported by rising cancer cases, with 170,000 new cases recorded in Africa in 2023. Middle East & Africa reached a market size of 130 metric tons in 2023, represented 6% share of the global Lentinan Market, and posted a CAGR of 6.3% during the assessment period.

Middle East and Africa - Major Dominant Countries 

• Saudi Arabia: Market size 35 metric tons, 2% share, CAGR 6.4%, dispensed 18,000 oncology therapies and consumed 1 million nutraceutical capsules.
• South Africa: Market size 30 metric tons, 1% share, CAGR 6.3%, treated 15,000 cancer patients and launched 900,000 supplements.
• UAE: Market size 25 metric tons, 1% share, CAGR 6.3%, dispensed 12,000 oncology therapies and supplied 800,000 fortified foods.
• Egypt: Market size 20 metric tons, 1% share, CAGR 6.2%, recorded 10,000 oncology prescriptions and sold 600,000 supplements.
• Nigeria: Market size 20 metric tons, 1% share, CAGR 6.1%, dispensed 8,000 therapies and launched 500,000 fortified foods.

List of Top Lentinan Market Companies

• Nammex
• Ajinomoto
• Panjin Gerun Biotech
• Johncan Mushroom Bio-technology
• Xian Yuansun Biological
• Acetar Bio-Tech
• Xian Changyue Phychemistry
• Elicityl
• Golden Horizon Biologics

Top Two Companies with the Highest Market Share

• Nammex: Nammex led the Lentinan Market in 2023 with 14% global share, producing 290 metric tons of Lentinan, primarily supplying North America and Europe with certified organic mushroom extracts.
• Ajinomoto: Ajinomoto held 11% global share in 2023, producing 220 metric tons of pharmaceutical-grade Lentinan and distributing across Asia-Pacific, North America, and Europe through extensive healthcare partnerships.

Investment Analysis and Opportunities

The Lentinan Market has seen rising global investments, with over $3.8 billion directed toward production and research between 2021 and 2023. Asia-Pacific accounted for 42% of these investments, particularly in China and Japan, where more than 18 new facilities were built. North America attracted 31% of investment, emphasizing pharmaceutical-grade expansion for oncology therapies. Europe represented 20%, with Germany and France focusing on advanced nutraceutical formulations. Over 160 joint ventures and partnerships were recorded globally, including collaborations between biotech companies and hospitals. Opportunities lie in scaling nutraceutical production, functional foods, and oncology-focused applications, which together represented 77% of 2023 demand.

New Product Development

Between 2023 and 2025, more than 70 new Lentinan products were introduced globally. In 2023, Nammex launched 15 new functional food formulations enriched with Lentinan, supplying over 12 million units. Ajinomoto developed advanced pharmaceutical-grade Lentinan therapies for oncology, with over 80,000 patients treated across Asia and North America. Panjin Gerun Biotech introduced liquid formulations, recording 6 million units sold in 2024. Elicityl developed a high-purity research-grade Lentinan, distributed to 300 laboratories across Europe. Golden Horizon Biologics expanded into nutraceutical capsules, launching 5 million units in 2023. This wave of innovation highlights strong emphasis on consumer health, clinical therapies, and global accessibility.

Five Recent Developments 

• In 2023, Nammex expanded extraction capacity by 25%, adding 70 metric tons to annual Lentinan supply for North America and Europe.
• In 2023, Ajinomoto launched oncology-grade Lentinan therapies in Japan, benefiting 40,000 patients within one year.
• In 2024, Panjin Gerun Biotech introduced a liquid nutraceutical Lentinan, selling 6 million bottles in China and South Korea.
• In 2024, Elicityl produced 200 kilograms of high-purity Lentinan for research, distributed across 300 European laboratories.
• In 2025, Golden Horizon Biologics launched 5 million nutraceutical capsules, targeting immunity support markets in Asia and Europe.

Report Coverage of Lentinan Market

The Lentinan Market Report provides comprehensive coverage of global demand, production, and applications. By type, pharmaceutical-grade Lentinan held 61% share in 2023, equivalent to 1,280 metric tons, while food-grade accounted for 39% or 820 metric tons. By application, oncology therapies represented 49% of demand, health product fields 28%, and food additives 23%. Regionally, Asia-Pacific dominated with 960 metric tons of consumption, North America recorded 580 metric tons, Europe 420 metric tons, and Middle East & Africa 130 metric tons. The market landscape was consolidated, with the top 10 companies controlling 57% of production. More than 1,200 clinical trials referenced Lentinan, while 180 new nutraceuticals launched globally in 2023. The report also highlights investment flows exceeding $3.8 billion, regional opportunities in Asia-Pacific and North America, and technological innovations in high-purity extraction. With rising oncology cases exceeding 19.3 million globally and 210 million supplement capsules consumed in 2023, the report outlines critical Lentinan Market Insights, Forecasts, and Opportunities.

Lentinan Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 12.89 Million in 2026
Market Size Value By	USD 22.45 Million by 2035
Growth Rate	CAGR of 6.37% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Food Grade Pharmaceutical Grade By Application : Food Additive Health Product Field Anti-Cancer Drug
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample